Efficacy of Levosimendan on postoperative low cardiac output syndrome of infants with congenital heart disease
10.3760/cma.j.issn.2095-428X.2020.01.009
- VernacularTitle: 左西孟旦在婴幼儿先天性心脏病术后低心排综合征中的疗效
- Author:
Ying HUA
1
;
Bin LI
1
;
Kaiyuan WU
1
;
Manman HU
1
;
Xuelan LIU
1
;
Xiaojing HUANG
2
Author Information
1. Intensive Care Unit of Children Heart Center, Henan Provincial People′s Hospital, Fuwai Central China Cardiovascular Hospital, Zhengzhou 450000, China
2. Department of Pharmacy, Henan Provincial People′s Hospital, Fuwai Central China Cardiovascular Hospital, Zhengzhou 450000, China
- Publication Type:Journal Article
- Keywords:
Infant;
Congenital heart disease;
Low cardiac output syndrome;
Levosimendan
- From:
Chinese Journal of Applied Clinical Pediatrics
2020;35(1):32-35
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of Levosimendan in the treatment of postoperative low cadiac output syndrome (LCOS) in infants with congenital heart disease (CHD).
Methods:Clinical data of patients with CHD developed postoperative LCOS in the Children Heart Center of Fuwai Central China Cardiovascular Hospital from January to December 2018 was collected.In patients that traditional vasoactive drugs failed to alleviate LCOS, the efficacy of continuous infusion of 0.1 μg/(kg·min) Levosimendan was observed.Besides, the mechanical ventilation time, ICU stay time, mortality, the changes of ejection fraction (EF) and central venous oxygen saturation (ScvO2) at the infusion of Levosimendan and 48 h after infusion, as well as the changes of heart rate (HR), systolic blood pressure (SBP), vasoactive drugs score (VIS) and lactic acid at the infusion of Levosimendan and 3 h, 6 h, 12 h, 24 h and 48 h after infusion were recorded.
Results:There were 29 cases, including 17 males (58.6%) and 12 females (41.4%), with median age of 2 (0.5, 40.0) months, median body mass of 4.7 (2.6, 13.5) kg, median mechanical ventilation time of 109.5 (42.5, 367.0) h, ICU stay time of 187.5 (83, 446) h, and 1 case died (3.4%). EF (48% vs.52%) and ScvO2 (53% vs.58%) increased 48 h after infusion, and the differences were statistically significant (all P<0.01). HR level (173 times/min, 176 times/min, 175 times/min, 173 times/min, 170 times/min, 170 times/min) and lactic acid level (4.72 mmol/L, 4.65 mmol/L, 4.34 mmol/L, 3.79 mmol/L, 3.28 mmol/L, 2.74 mmol/L) gradually decreased after infusion, and the differences of both between the beginning of infusion and 48 h after infusion were statistically significant (P=0.029); SBP decreased and then increased (74 mmHg, 70 mmHg, 71 mmHg, 73 mmHg, 74 mmHg, 75 mmHg, 1 mmHg=0.133 kPa), and VIS increased and then decreased (26 scores, 27 scores, 27 scores, 26 scores, 25 scores, 25 scores) at different time points after infusion, however, the data of both between the beginning of infusion and 48 h after infusion had no significant differences (P=0.294, 0.151).
Conclusions:Levosimendan can increase EF, enhance myocardial contractility and systemic tissue perfusion, thus improving the prognosis, when Levosimendan was applied for the treatment of postoperative LCOS of infants with CHD.
